

Noriko Shoii1; Chie Yokovama1; Naohiro Kurivama1; Jun Watanabe2; Haruo Hosoda2; Joii Seta2; Norivuki Iwasaki2

¹YMC Co., Ltd., Komatsu, Japan; ²Bruker Daltonics K, K., Yokohama, Japan

Introduction

LC/MS is significantly important in gualitative and the guantitative analysis in the drug metabolism and the drug kinetics today.

MD:

----> R2=COCH

MB:

M2:

R1=CH

R3=NHCH

R2-H

M4:

R1=H

R2=H

R3=N(CH₂)

R1=H

R2=COCH

R3=NHCH₂

R1=CH

• Mx:

Diltiazezm

(DTZ):

R1=CH

R2=COCH

R3=N(CH₃)₂

R1-H

M1 ·

R1=CH

R2=H

R3=N(CH₃)₂

R2=COCH

R3=N(CH₂)₂

R2=COCH

R3=NHCH

R1=CH₂

R3=NH

MF:

The separation with LC is a very big factor because it needs to measure the metabolites from among a complex matrix, and typically a separation can be obtained by using slow gradient at long measurement time (i.e. about 60 min per one measurement). Recently a lot of the columns with a small particle diameter are used in many applications and the high resolution and the speed-up measurement in LC analysis become in common. This time, we examined high sensitivity, high throughput metabolite analysis by using LC/TOF-MS with a small particle packed column Fig.1 micrOTOF II

Device & Method

Sample preparation In vitro metabolism of Diltiazem (DTZ) in human liver

S9: DTZ, NADPH regeneration system solution A (NADP+, Glucose-6-phosphate, MgCl₂ in H₂O), NADPH regeneration system solution B (Glucose-6-phosphate dehydrogenase in sodium citrate buffer), human liver S9 were mixed in 100 mM phosphate buffer (pH 7.4). The mixture was incubated at 37 deg C overnight (approx, 17 hrs). The control sample was prepared without DTZ added. [Final concentration in incubation mixture; 100 µM DTZ, 1.6 mM NADP, 3.3 mM Glucose-6-phosphate, 0.4 U/mL Glucose-6-phosphate dehydrogenase, 3.3 mM MgCl₂, 2 mg/mL S9 protein

Solid phase extraction (SPE) of incubation mixture: The

incubation mixture was extracted on YMC Dispo SPE C18 column (100 mg/mL) as follows and injected onto LC/TOF-MS.

1. Condition with 2 ml MeOH 2. Equilibrate with 2 mL 0.1% CH₂COOH 3. Load 250 µL sample 4. Flute with 1 ml MeOH 5. Dry extract and resolve in 500 μL H₂O

LC/TOE-MS conditions

HPLC: Agilent 1200SL system

Column: Hydrosphere C18 (YMC Co., Ltd.). 5 um, 150x2.0 mmI.D Eluent: A) 20 mM HCOONH₄ B) Methanol Gradient: 25%B (0-3.0min), 25-80%B (3-21min), 80%B (21-24min)

Flow Rate: 0.2 mL/min Column Oven Temperature: 37 deg C Injection volume: 3 µL Mass instrument: micrOTOF II (Bruker Daltonics) ESI, positive mode, m/z 100 - 1000

High throughput LC/TOF-MS conditions

HPLC: Agilent 1200SL system Column: YMC-UltraHT Hvdrosphere C18 (YMC Co., Ltd.) 2 µm, 50x2.0 mmI.D. Eluent: A) 20 mM HCOONH, B) Methanol Gradient: 25%B (0-0.5min), 25-80%B (0.5-3.5min), 80%B (3.5-4min) Flow Rate: 0.4 ml /min Column Oven Temperature: 37 deg C Injection volume: 1 µL (reduced to 1/3) Mass instrument: micrOTOF II (Bruker Daltonics) ESI, positive mode, m/z 100 - 1000



Fig.2 Structure of Diltiazem and its metabolites

Fig.3 Analysis of DTZ metabolites by LC/TOF-MS and software for metabolite identification (Metabolite Tool)

Experimental & Results

First of all, samples were acquired on the general LC/TOF-MS condition; column particle diameter 5 um, column size 150 X 2 mm, flow rate 0.2 ml/min, run time 24 min, and injection volume 3 ul. As a result, an excellent separation was obtained, and a lot of metabolites such as de-methylation (-CH₂), de-ethylation (-C₂H₄) and de-acetylation (-COCH₂) were detected (Figure 3).

The metabolites were confirmed by high resolution extracted ion chromatogram (hrEIC) of their precise mass which is available in using the high resolution of TOF, and the formula and isotope pattern analysis to the mass spectrum of the detected peak (Figure 4, Table 1).



Fig.4 Confirmation of the de-acetylated metabolite by the high resolution of TOF and the formula/isotope pattern analysis

Table 1 List of the main metabolites detected

Metabolite	Formula	m/z expect	m/z detect	⊿m/z (mDa)	RT (min)
Drug	C22H26N2O4S	415.1686	415.1700	1.38	21.6
-CH2	C21H24N2O4S	401.1530	401.1535 / 401.1533	-0.53 / -0.35	17.8 / 18.4
-COCH2	C20H25N2O3S	373.1580	373.1590	-0.98	19.9
-(CH2)2	C20H22N2O4S1	387.1373	387.1366 / 387.1380	0.68 / -0.65	15.4 / 18.9
-CO(CH2)2	C19H22N2O3S	359.1424	359.1416 / 359.1425	0.81 / -0.08	16.1 / 16.9

Next, samples were acquired on the high throughput LC/TOF-MS condition that the particle diameter of the column was reduced to 2 µm, the length of the column was shortened to 50 mm, and the flow rate was fastened to 0.4 ml/min in order to raise throughput. As the sensitivity improvement was expected, the injection volume was reduced to 1 ul. As a result, all metabolites that had been obtained on the previous condition were detected. It was found that sensitivity has improved because detection intensity was equal to the previous condition though the injection volume was reduced. In addition, it was found to be able to maintain high resolution even if the column length was shortened by reducing the particle size because the resolution of the peak in chromatogram was equally to the previous condition (Figure 5).



Conclusions

- 1. Metabolite analysis using LC/TOF-MS with small particle size column achieved speed-up of analysis time and provided excellent separation.
- 2. The metabolites were confirmed without MS/MS analysis because of the excellent performance of the high resolution TOF, the formula and isotope pattern analysis.

YMC Co., Ltd. / Bruker Daltonics K. K.